Julphar Gulf Pharmaceutical Industries has announced the appointment of the company’s Associate Director Finance, Laurent de Chazeaux, as Acting Chief Financial Officer – effective immediately. Laurent replaces Jerome Carle, who has been appointed General Manager of Julphar.
Commenting on the appointment of Laurent de Chazeaux as Acting CFO, Julphar’s Chairman His Highness Sheikh Faisal Bin Saqr Al Qasimi stated: “I trust Laurent is an established financial executive with extensive background overseeing finance organizations. With him leading the Finance team, I am confident that we will be well-positioned to enter the next phase of our strategy execution.”
“I am much honored to have been appointed to this role,” said Laurent de Chazeaux. “I will work closely with the Executive team and will focus on driving performance to help the company achieve its next stages of growth.”
As Acting CFO of Julphar, Laurent de Chazeaux will be responsible for leading Julphar’s finance department and keeping accurate financial records. He will be in charge of the administrative and risk management operations and will develop financial strategies in line with the company’s objectives. He will report to the company’s General Manager, Jerome Carle.
Over the last 20 years, Laurent de Chazeaux has worked in a number of senior finance roles in the pharmaceutical industry and in investment banking. He spent several years working for Cowen, where he was in charge of analyzing performances of midsize European pharmaceutical companies, and before joining Julphar as Associate Director Finance in June 2017, he worked at Sanofi and as Finance Director at AstraZeneca. Laurent has a degree from EDHEC Business School (France) in International Management and has been living in the Middle East for the past 10 years.
Established in 1980, Julphar is one of the largest pharmaceutical manufacturers in Middle East and North Africa, producing over 200 branded products across 16 facilities. Julphar’s mission is to offer high quality medicines at affordable prices. Our product portfolio includes Biotechnology, Wound and Women Care, Adult and Pediatric General Medicines, Gastro and Pain Management, Cardio-Metabolism, Diabetes Solutions and Consumer range. Julphar employs more than 3,000 people around the world and registered revenue of AED 1.45 billion in 2016. For more information, please visit http://www.julphar.net.